Table 1.
Baseline characteristics.
| Total (N = 123) | ||
|---|---|---|
| Age (yrs) | Median (Q1, Q3)a | 39 (33, 45) |
| Sex | Female | 70 (57%) |
| Prior regimenb | TDF+3TC+NVP | 4 (3%) |
| ZDV+3TC+EFV | 8 (7%) | |
| ZDV+3TC+NVP | 26 (21%) | |
| d4T+3TC+EFV | 21 (17%) | |
| d4T+3TC+NVP | 63 (51%) | |
| ddI+3TC+NVP | 1 (1%) | |
| Total ARV exposure | Median (Q1, Q3)a | 3 (2, 4) |
| <1 years | 9 (7%) | |
| 1 – <3 years | 44 (36%) | |
| 3+ years | 70 (57%) | |
| HIV-1 RNA (log10 | Median (Q1, Q3)a | 4.34 (3.75, 4.92) |
| (copies/mL)) | < 3.00 | 4 (3%) |
| 3.00–3.99 | 38 (31%) | |
| 4.00 – <4.99 | 60 (49%) | |
| 5.00 – <5.29 | 14 (11%) | |
| 5.3 | 7 (6%) | |
| CD4 cell count | Median (Q1, Q3)a | 164 (82, 268) |
| (cells/mm3) | < 50 | 19 (15%) |
| 50–199 | 51 (41%) | |
| 200–349 | 39 (32%) | |
| 350 | 14 (11%) |
a
Q1 and Q3 represent the 25th and 75th percentiles, respectively.
b
Prior regimen: most recent regimen before enrolling in A5230; Medication abbreviations: 3TC- lamivudine, EFV- efavirenz, TDF-tenofovir, NVP- nevirapine, ZDV- zidovudine, D4T- stavudine, DDI- didanosine.